Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol Myers (BMY), Nabriva (NBRV) and Sanofi (OtherSNYNF)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol Myers (BMYResearch Report), Nabriva (NBRVResearch Report) and Sanofi (SNYNFResearch Report).

Bristol Myers (BMY)

BMO Capital analyst Evan Seigerman reiterated a Buy rating on Bristol Myers today and set a price target of $81.00. The company’s shares closed last Wednesday at $73.59, close to its 52-week high of $73.74.

According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 7.9% and a 49.0% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Mirati Therapeutics, and Gilead Sciences.

Currently, the analyst consensus on Bristol Myers is a Moderate Buy with an average price target of $71.86.

See the top stocks recommended by analysts >>

Nabriva (NBRV)

In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Nabriva. The company’s shares closed last Wednesday at $0.45, close to its 52-week low of $0.40.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 13.2% and a 41.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Nabriva.

Sanofi (SNYNF)

In a report released today, Dominic Lunn from Credit Suisse maintained a Buy rating on Sanofi, with a price target of EUR105.00. The company’s shares closed last Wednesday at $100.58.

Lunn has an average return of 0.3% when recommending Sanofi.

According to TipRanks.com, Lunn is ranked #6207 out of 7928 analysts.

Sanofi has an analyst consensus of Moderate Buy, with a price target consensus of $119.28, implying a 18.6% upside from current levels. In a report issued on March 16, Jefferies also maintained a Buy rating on the stock with a EUR120.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BMY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos